Hui Sheng Biopharma bags nearly $86m in Series A+ round

Hui Sheng Biopharmaceutical, a subsidiary of Hong Kong-listed Sihuan Pharmaceutical Holdings Group, has secured 580 million yuan ($85.6 million) in a Series A+ round, bringing its post-investment valuation at 5.58 billion yuan ($823.6 million), according to a filing on the Hong Kong Stock Exchange on January 3.